242 related articles for article (PubMed ID: 24186700)
1. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients.
Price D; Small I; Haughney J; Ryan D; Gruffydd-Jones K; Lavorini F; Harris T; Burden A; Brockman J; King C; Papi A
Prim Care Respir J; 2013 Dec; 22(4):439-48. PubMed ID: 24186700
[TBL] [Abstract][Full Text] [Related]
2. Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: A real-life effectiveness and cost impact evaluation.
Wan Yau Ming S; Haughney J; Small I; Wolfe S; Hamill J; Gruffydd-Jones K; Daly C; Soriano JB; Gardener E; Skinner D; Stagno d'Alcontres M; Price DB
Respir Med; 2017 Aug; 129():199-206. PubMed ID: 28732831
[TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis of a fixed-dose combination of fluticasone propionate and formoterol fumarate (FP/FORM) in a pressurized metered-dose inhaler (pMDI) for asthma.
Dunlop W; Heron L; Fox G; Greaney M
Adv Ther; 2013 Oct; 30(10):933-44. PubMed ID: 24194361
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma.
Gerzeli S; Rognoni C; Quaglini S; Cavallo MC; Cremonesi G; Papi A
Clin Drug Investig; 2012 Apr; 32(4):253-65. PubMed ID: 22352412
[TBL] [Abstract][Full Text] [Related]
5. Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective.
Paggiaro P; Patel S; Nicolini G; Pradelli L; Zaniolo O; Papi A
Respir Med; 2013 Oct; 107(10):1531-7. PubMed ID: 23916740
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
Doull I; Price D; Thomas M; Hawkins N; Stamuli E; Tabberer M; Gosden T; Rudge H
Curr Med Res Opin; 2007 May; 23(5):1147-59. PubMed ID: 17519082
[TBL] [Abstract][Full Text] [Related]
7. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
Johansson G; Andreasson EB; Larsson PE; Vogelmeier CF
Pharmacoeconomics; 2006; 24(7):695-708. PubMed ID: 16802845
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
[TBL] [Abstract][Full Text] [Related]
10. A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta-agonists for asthma maintenance treatment in Germany.
Aballéa S; Cure S; Vogelmeier C; Wirén A
Int J Clin Pract; 2008 Dec; 62(12):1870-9. PubMed ID: 18803555
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
O'Connor RD; Nelson H; Borker R; Emmett A; Jhingran P; Rickard K; Dorinsky P
Pharmacoeconomics; 2004; 22(12):815-25. PubMed ID: 15294013
[TBL] [Abstract][Full Text] [Related]
12. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
FitzGerald JM; Boulet LP; Follows RM
Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
[TBL] [Abstract][Full Text] [Related]
13. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2003; 21(13):951-89. PubMed ID: 12959627
[TBL] [Abstract][Full Text] [Related]
14. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
Bousquet J; Boulet LP; Peters MJ; Magnussen H; Quiralte J; Martinez-Aguilar NE; Carlsheimer A
Respir Med; 2007 Dec; 101(12):2437-46. PubMed ID: 17905575
[TBL] [Abstract][Full Text] [Related]
15. Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life.
Price DB; Williams AE; Yoxall S
Respir Res; 2007 Jul; 8(1):46. PubMed ID: 17610727
[TBL] [Abstract][Full Text] [Related]
16. Health-care utilization and costs with fluticasone propionate and fluticasone propionate/salmeterol in asthma patients at risk for exacerbations.
Hagiwara M; Delea TE; Stanford RH
Allergy Asthma Proc; 2014; 35(1):54-62. PubMed ID: 24433597
[TBL] [Abstract][Full Text] [Related]
17. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
Markham A; Jarvis B
Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
[TBL] [Abstract][Full Text] [Related]
18. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
Frois C; Wu EQ; Ray S; Colice GL
Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
[TBL] [Abstract][Full Text] [Related]
19. Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group study.
Aalbers R
Clin Drug Investig; 2010; 30(7):439-51. PubMed ID: 20528000
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
Sheth K; Borker R; Emmett A; Rickard K; Dorinsky P
Pharmacoeconomics; 2002; 20(13):909-18. PubMed ID: 12381242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
